Anixa is a biopharmaceutical company that is developing multiple initiatives targeting cancer and infectious diseases. Anixa's therapeutic portfolio encompasses a cancer vaccine technology focused on immunization against ?-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program utilizing a unique form of CAR-T, named chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program concentrated on hindering specific viral protein function. Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company specializing in the development of innovative topical treatments for diseases resulting from HPV infection. The primary focus is to prevent cancer by treating the precancerous lesions caused by HPV. Their lead programs are currently undergoing clinical trials for high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3). Founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego, the company leverages his antiviral expertise as a co-founder of Triangle Pharmaceuticals and Chimerix.